Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Joins Nasdaq-100

SAN FRANCISCO, Dec. 17 - Invitrogen will join 12 other companies that will be added to the Nasdaq-100 Index next Monday.

 

The Nasdaq-100, the 100 largest non-financial stocks on the Nasdaq Stock Market, is re-ranked every December. The rankings are based on a company's market capitalization, computed using closing prices as of October 31 and the publicly reported total shares outstanding as of November 30.

 

At the time of ranking, Invitrogen's market capitalization was $3.2 billion, according to Nasdaq.

 

"Our appointment to the Index is a testament to Invitrogen's rapid growth and consistent performance throughout its history and since becoming a public company in 1999," Lyle Turner, CEO of Invitrogen, said in a statement.

 

Eight of this year's 13 additions to the Nasdaq-100 are life science-oriented companies. Corporations listed in the Index are included in the Nasdaq-100 Index Tracking Stock, the world's most actively traded exchange-traded fund, according to Nasdaq.

 

In early December, Invitrogen, based in San Diego, Calif., said it plans to post $628 million in revenues for the year, which will surpass by 155 percent 2000 sales.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.